FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W95486521> ?p ?o ?g. }

• W95486521 endingPage "6" @default.
• W95486521 startingPage "231" @default.
• W95486521 abstract "Genelabs is developing GL-701 (prasterone), oral dehydroepiandrosterone (DHEA), for the potential treatment of systemic lupus erythematosus (SLE) [154020]. In September 2000, the company completed submission of its rolling NDA, begun in May 2000 [340361], [355642], [361381], [380239], [383545]. In October 2000, the FDA granted the company's NDA Priority Review designation [387020]. Genelabs began its NDA submission for GL-701 in May 2000, by submitting the complete clinical, statistical and human pharmacokinetic sections to the FDA. This includes all the human efficacy and safety data for the NDA [368932]. In March 1999, Genelabs received Fast Track designation for GL-701 from the US FDA, allowing the development and review of an NDA to be expedited [319963]. Genelabs met with the US FDA in November 1999 to present the data from the two phase III trials in women and was advised by the FDA that its NDA proposal appeared adequatefor submission [348192], [361381]. Because of the public domain nature of DHEA, Genelabs was not certain that it would obtain patent protection. In the US it received Orphan Drug designation, providing seven years of exclusive marketing rights, and in October 1996, Genelabs received US-05567696, covering the use of GL-701 in lupus patients to reduce their dosage of concomitant corticosteroids [222741], [329646]. The US FDA has also granted Subpart E designation to GL-701, which permits expedited development [169754], [222741]. Genelabs licensed the product exclusively worldwide from Stanford University, which performed the early-stage clinical studies. The Asian marketing rights have been licensed to Genelabs Biotechnology Ltd (GBL), a joint investment with the government of Taiwan [229812]. In January 2001, analysts at UBS Warburg predicted that GL-701 would be launched in 2001, and reach sales of US $ 90 million by 2004 [398731]." @default.
• W95486521 created "2016-06-24" @default.
• W95486521 creator A5043672106 @default.
• W95486521 date "2001-02-01" @default.
• W95486521 modified "2023-09-25" @default.
• W95486521 title "GL-701 Genelabs." @default.
• W95486521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11816836" @default.
• W95486521 hasPublicationYear "2001" @default.
• W95486521 type Work @default.
• W95486521 sameAs 95486521 @default.
• W95486521 citedByCount "1" @default.
• W95486521 crossrefType "journal-article" @default.
• W95486521 hasAuthorship W95486521A5043672106 @default.
• W95486521 hasConcept C126322002 @default.
• W95486521 hasConcept C512399662 @default.
• W95486521 hasConcept C535046627 @default.
• W95486521 hasConcept C60644358 @default.
• W95486521 hasConcept C71924100 @default.
• W95486521 hasConcept C75480439 @default.
• W95486521 hasConcept C86803240 @default.
• W95486521 hasConceptScore W95486521C126322002 @default.
• W95486521 hasConceptScore W95486521C512399662 @default.
• W95486521 hasConceptScore W95486521C535046627 @default.
• W95486521 hasConceptScore W95486521C60644358 @default.
• W95486521 hasConceptScore W95486521C71924100 @default.
• W95486521 hasConceptScore W95486521C75480439 @default.
• W95486521 hasConceptScore W95486521C86803240 @default.
• W95486521 hasIssue "2" @default.
• W95486521 hasLocation W954865211 @default.
• W95486521 hasOpenAccess W95486521 @default.
• W95486521 hasPrimaryLocation W954865211 @default.
• W95486521 hasRelatedWork W1966768512 @default.
• W95486521 hasRelatedWork W2007422794 @default.
• W95486521 hasRelatedWork W2090374979 @default.
• W95486521 hasRelatedWork W2426703416 @default.
• W95486521 hasRelatedWork W2590183723 @default.
• W95486521 hasRelatedWork W2746282385 @default.
• W95486521 hasRelatedWork W2920807914 @default.
• W95486521 hasRelatedWork W3203879531 @default.
• W95486521 hasRelatedWork W4285031144 @default.
• W95486521 hasRelatedWork W4288723778 @default.
• W95486521 hasVolume "2" @default.
• W95486521 isParatext "false" @default.
• W95486521 isRetracted "false" @default.
• W95486521 magId "95486521" @default.
• W95486521 workType "article" @default.